GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Forward PE Ratio

Rising Biosciences (Rising Biosciences) Forward PE Ratio : 0.00 (As of Jun. 15, 2024)


View and export this data going back to . Start your Free Trial

What is Rising Biosciences Forward PE Ratio?

Rising Biosciences's Forward PE Ratio for today is 0.00.

Rising Biosciences's PE Ratio without NRI for today is 9999.00.

Rising Biosciences's PE Ratio for today is 9999.00.


Rising Biosciences Forward PE Ratio Historical Data

The historical data trend for Rising Biosciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Forward PE Ratio Chart

Rising Biosciences Annual Data
Trend
Forward PE Ratio

Rising Biosciences Quarterly Data
Forward PE Ratio

Competitive Comparison of Rising Biosciences's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Rising Biosciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rising Biosciences's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rising Biosciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Rising Biosciences's Forward PE Ratio falls into.



Rising Biosciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Rising Biosciences  (GREY:RBII) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Rising Biosciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rising Biosciences (Rising Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
1180 Cleveland Road, Sandusky, OH, USA, 44870
Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.

Rising Biosciences (Rising Biosciences) Headlines

From GuruFocus

PAOG Officially Appoints Karl Riedel as New CEO and President

By Marketwired Marketwired 02-11-2019